<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113849</url>
  </required_header>
  <id_info>
    <org_study_id>IN_COV_101</org_study_id>
    <nct_id>NCT05113849</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19)</brief_title>
  <official_title>A Phase 1, Open-label, Dose-escalation Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults Aged at 19 to 55 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first in human, phase I, open-label, dose-escalation study to assess the safety,&#xD;
      reactogenicity, and immunogenicity of a SARS-CoV-2 Vaccine (IN-B009) in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total of 40 participants will be enrolled in 3 institutions : Seoul National University&#xD;
      Hospital, Jeonbuk National University Hospital, and Chungbuk National University Hospital.&#xD;
&#xD;
      Safety, reactogenicity, and immunogenicity will be evaluated in healthy participants with&#xD;
      administration of IN-B009 (Injected twice, 21-day-interval).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence rate of Immediate Adverse Reaction (IAR)</measure>
    <time_frame>Through 30 minutes post each vaccination (2 hours for sentinel participants)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence rate of solicited local and systemic AE</measure>
    <time_frame>Through Day 7 post each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence rate of unsolicited AE</measure>
    <time_frame>Through Day 28 post each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence rate of SAEs, MAAEs, AESIs</measure>
    <time_frame>Through Day 365 post last vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GMT of Anti-SAS-CoV-2 RBD IgG measured with ELISA</measure>
    <time_frame>Through Day 365 post last vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GMFR of Anti-SAS-CoV-2 RBD IgG from baseline measured with ELISA</measure>
    <time_frame>Through Day 365 post last vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants achieving a greater than or equal to 4-fold rise from baseline in IgG titer</measure>
    <time_frame>Through Day 365 post last vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GMT of Neutralizing anti-SARS-CoV-2 measured with live virus neutralization assay</measure>
    <time_frame>Through Day 365 post last vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GMFR of Neutralizing anti-SARS-CoV-2 measured with live virus neutralization assay</measure>
    <time_frame>Through Day 365 post last vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants achieving a greater than or equal to 4-fold rise from baseline in wild-type neutralizing antibody titer</measure>
    <time_frame>Through Day 365 post last vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cell-mediated response</measure>
    <time_frame>Through Day 28 post last vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Cohort A (Low-dose group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IN-B009 (Low-dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (High-dose group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IN-B009 (High-dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IN-B009 (Low-dose)</intervention_name>
    <description>Two doses, intramuscular injection</description>
    <arm_group_label>Cohort A (Low-dose group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IN-B009 (High-dose)</intervention_name>
    <description>Two doses, intramuscular injection</description>
    <arm_group_label>Cohort B (High-dose group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants between the ages of 18 and 55 years.&#xD;
&#xD;
          -  Participants considered 'healthy' to be eligible for study participation.&#xD;
&#xD;
          -  Participants who are willing and able to comply with all scheduled visits and other&#xD;
             study procedures.&#xD;
&#xD;
          -  Participants with Body mass index (BMI) within the normal range.&#xD;
&#xD;
          -  Participants with deltoid muscle capable of IP injection.&#xD;
&#xD;
          -  Those that agreed to using medically approved contraception.&#xD;
&#xD;
          -  Female participants with potential pregnancy- Those that used medically approved&#xD;
             contraception and has negative result at the pregnancy test.&#xD;
&#xD;
          -  Capable of giving personal signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant symptoms prior to IP injection.&#xD;
&#xD;
          -  Confirmed to be COVID-19 RT-PCR positive or to have made close contact with SARS-CoV-2&#xD;
             infected patient.&#xD;
&#xD;
          -  History of virologically-confirmed SARS, MERS, or COVID-19.&#xD;
&#xD;
          -  History of congenital or acquired immunodeficiency or autoimmune diseases.&#xD;
&#xD;
          -  Positive result of hepatitis B, C, RPR test, or HIV.&#xD;
&#xD;
          -  History of disorder that inhibits intramuscular injection of the vaccine.&#xD;
&#xD;
          -  History of hypersensitivity and severe allergic reaction to any of the components of&#xD;
             IP.&#xD;
&#xD;
          -  History of malignant tumor within 5 years prior to the first IP injection.&#xD;
&#xD;
          -  Clinically significant chronic diseases that could cause safety concerns regarding&#xD;
             COVID-19.&#xD;
&#xD;
          -  Scheduled of , or history of surgery under general anaesthesia prior to first IP&#xD;
             injection,&#xD;
&#xD;
          -  Female participant that is pregnant or is currently breastfeeding.&#xD;
&#xD;
          -  Smoker or history of smoking within 12 weeks prior to first IP injection.&#xD;
&#xD;
          -  Previous vaccination or treatment for prevention of COVID-19.&#xD;
&#xD;
          -  Vaccination prior to the first IP injection or scheduled of vaccination after second&#xD;
             IP injection.&#xD;
&#xD;
          -  Treated with immunoglobulin and/or blood/blood components prior to first IP injection.&#xD;
&#xD;
          -  Chronic use of immunosuppressant prior to first IP injection.&#xD;
&#xD;
          -  Participated in other clinical study prior to first IP injection, or scheduled to&#xD;
             participate in other study during the study period.&#xD;
&#xD;
          -  Healthcare worker or emergency response personnel.&#xD;
&#xD;
          -  Conditions that may influence the evaluation of the study objectives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Jin Jang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Min Geol Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jeonju National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Ki Hwang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungbuk National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naree Shin, MS</last_name>
    <phone>+82-2-6477-0271</phone>
    <email>naree.shin@inno-n.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Chungju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min-Gul Kim, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jeonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Ki Hwang, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In-Jin Jang, MD, PhD</last_name>
      <phone>+82-2-2072-1910</phone>
      <email>ijjang@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

